We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
-6.04%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$1.45B
AUM Growth
-$206M
Cap. Flow
+$38.7M
Cap. Flow %
2.66%
Top 10 Hldgs %
69.2%
Holding
57
New
2
Increased
7
Reduced
7
Closed
3

Top Buys

Rank Stock Value
1
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$40.5M
2
GERN icon
Geron
GERN
+$17M
3
VERA icon
Vera Therapeutics
VERA
+$14.3M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$5.48M
5
CLDX icon
Celldex Therapeutics
CLDX
+$4.6M

Top Sells

Rank Stock Value
1
HRMY icon
Harmony Biosciences
HRMY
+$12.8M
2
EPIX
ESSA Pharma
EPIX
+$10.6M
3
WHWK
Whitehawk Therapeutics
WHWK
+$10.2M
4
LRMR icon
Larimar Therapeutics
LRMR
+$4.31M
5
MREO
Mereo BioPharma
MREO
+$4.02M

Sector Composition

Rank Sector Weight
1 Healthcare 84.74%
2 Financials 11.77%
3 Materials 3.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELEV
51
DELISTED
Elevation Oncology
ELEV
$1.25M 0.09%
496,844
– –
DTIL icon
52
Precision BioSciences
DTIL
$207M
$432K 0.03%
4,675
– –
MTCR
53
DELISTED
Metacrine, Inc. Common Stock
MTCR
$89K 0.01%
146,426
– –
EIGR
54
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$35K ﹤0.01%
139
– –
EPIX
55
DELISTED
ESSA Pharma
EPIX
– –
-744,058
Closed -$10.6M
LRMR icon
56
Larimar Therapeutics
LRMR
$430M
– –
-399,830
Closed -$4.31M
ZGNX
57
DELISTED
Zogenix, Inc.
ZGNX
– –
-105,000
Closed -$1.71M
1 2
3

Similar funds

FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.4% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM
CCM
Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return
TIM
Tortoise Investment Management White Plains, New York $1.21B AUM 13.04% 1-Year Est. Return
CS
Central Securities New York $1.21B AUM 19.91% 1-Year Est. Return
KOC
Koss-Olinger Consulting Gainesville, Florida $1.19B AUM 15.91% 1-Year Est. Return

Vivo Capital's Q1 2022 Portfolio in Review

As of Q1 2022, Vivo Capital held 57 positions worth $1.45B, down 12% from $1.66B the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Vivo Capital's Q1 2022 filing shows 2 new, 7 increased, 7 reduced and 3 closed positions. Its largest new stake was Geron: 15,238,095 shares worth $20.7M. The largest sale was Harmony Biosciences, an estimated $12.8M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 86% a quarter earlier, followed by Financials and Materials.

  • Vivo Capital's largest Q1 2022 buy was Geron: 15,238,095 shares worth $20.7M.
  • Vivo Capital added most to Sierra Oncology, Inc. Common Stock in Q1 2022, an estimated $40.5M increase.
  • Vivo Capital's biggest Q1 2022 reduction was Harmony Biosciences, cutting an estimated $12.8M.
  • Vivo Capital fully exited ESSA Pharma in Q1 2022, selling an estimated $10.6M.
  • Vivo Capital's ten largest holdings make up 69% of its $1.45B portfolio in Q1 2022.
  • Vivo Capital opened 2 new positions and closed 3 in Q1 2022.
  • Vivo Capital's portfolio value fell 12% quarter-over-quarter to $1.45B.

Based on Vivo Capital's 13F filing for Q1 2022, filed 13 May 2022.